INS NYC 2024 Program

Custom Content	Poster Session 09 Program Schedule 02/16/2024 03:30 pm - 04:45 pm Room: Shubert Complex (Posters 1-60) Poster Session 09: Epilepsy \| Oncology \| MS \| Infectious Disease Final Abstract #3 Poster Symposium: Neuropsychology in the Era of SARS-CoV-2 — Abstract 2 An Overview of Biomarker Research in PASC-Associated Cognitive Deficits Lucette Cysique, University of new south whales, Sydney, Australia Category: Other Keyword 1: cognitive functioning Keyword 2: neuroimmunology Objective: Provide an introduction of the pathogenesis of Post-Acute Sequelae of SARS-CoV-2 (PASC)-associated cognitive deficits by reviewing the research from laboratory biomarkers research in the blood and cerebrospinal fluid. Participants and Methods: Narrative review of the literature inclusive of studies with well-defined cognitive and/or neuropsychological outcomes in PASC assessing their association with laboratory-based biomarkers. Sources documents will be acknowledged and provided as links. Results: The talk will provide an overview of the current research into the biomarkers, namely clinical neuroscience assays (immune, neurology, vascular, metabolic, microbiome) in PASC and associated cognitive deficits. To determine the strength of evidence in the role of biomarkers in PASC-associated cognitive deficits, the talk will emphasize issues relating to the quality of the cognitive/neuropsychology outcomes, effects of acute COVID-19 severity, viral effects (strains, neuroinvasive/neurotropic potential), patients’ characteristics (demographics, pre-existing comorbidities, health disparities), the question of appropriate controls, timeline of the disease and timeline of assessments. Directions for future research will be provided. Conclusions: Several biomarkers are emerging as potential markers of PASC-associated cognitive deficits. More complex analyses in large samples are needed to further determine their sensitivity, specificity, and prognostic value. Research will also need to adapt quickly in the case new viral strains emerge and have a different brain impact.

Custom Content

Poster Session 09 Program Schedule

02/16/2024
03:30 pm - 04:45 pm
Room: Shubert Complex (Posters 1-60)

Poster Session 09: Epilepsy | Oncology | MS | Infectious Disease

Final Abstract #3

Poster Symposium: Neuropsychology in the Era of SARS-CoV-2 — Abstract 2

An Overview of Biomarker Research in PASC-Associated Cognitive Deficits

Lucette Cysique, University of new south whales, Sydney, Australia

Category: Other

Keyword 1: cognitive functioning
Keyword 2: neuroimmunology

Objective:

Provide an introduction of the pathogenesis of Post-Acute Sequelae of SARS-CoV-2 (PASC)-associated cognitive deficits by reviewing the research from laboratory biomarkers research in the blood and cerebrospinal fluid.

Participants and Methods:

Narrative review of the literature inclusive of studies with well-defined cognitive and/or neuropsychological outcomes in PASC assessing their association with laboratory-based biomarkers. Sources documents will be acknowledged and provided as links.

Results:

The talk will provide an overview of the current research into the biomarkers, namely clinical neuroscience assays (immune, neurology, vascular, metabolic, microbiome) in PASC and associated cognitive deficits. To determine the strength of evidence in the role of biomarkers in PASC-associated cognitive deficits, the talk will emphasize issues relating to the quality of the cognitive/neuropsychology outcomes, effects of acute COVID-19 severity, viral effects (strains, neuroinvasive/neurotropic potential), patients’ characteristics (demographics, pre-existing comorbidities, health disparities), the question of appropriate controls, timeline of the disease and timeline of assessments. Directions for future research will be provided.

Conclusions:

Several biomarkers are emerging as potential markers of PASC-associated cognitive deficits. More complex analyses in large samples are needed to further determine their sensitivity, specificity, and prognostic value. Research will also need to adapt quickly in the case new viral strains emerge and have a different brain impact.